ClinicalTrials.gg
CompletedNCT00513370PRIDEUpdated Apr 11, 2011Results posted

A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis

A Phase 3 interventional study of Humira (adalimumab) in Psoriasis, sponsored by Abbott. Completed at 27 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-11.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
203
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
21st of 48
203 · median 148
Started
2007
with 1 other
Phase 3
26 of 48
1 open now
Registered
4th of 48
by date
Lead sponsor
11 of 48
Abbott

Among the 48 studies testing adalimumab in Psoriasis, this one is the 21st largest by enrollment, is one of 2 that started in 2007, is one of 26 in phase 3, and was the 4th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

To evaluate the safety profile, the effectiveness and the economic impact of adalimumab when used for the treatment of subjects with active plaque psoriasis who have not adequately responded to prior psoriasis therapy.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • adalimumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a clinical diagnosis of psoriasis for at least 6 months prior to the Screening, as determined by subject interview of his/her medical history and confirmation of diagnosis through physical examination by the investigator
  • Subject must have stable plaque psoriasis for at least 2 months prior to the Screening, as determined by subject interview of his/her medical history
  • Subject has moderate to severely active plaque psoriasis at Baseline defined as: BSA (Body Surface Area) > 10% and a Psoriasis Area and Severity Index (PASI) > 12
  • Subject has active psoriasis despite treatment with topical agents
  • Subject has failed to respond to, is intolerant to or unable to access phototherapy
  • Subject has failed to respond to, is intolerant to or has for at least two of the following therapies:

    • CyA (Cyclosporine A)
    • MTX (Methotrexate)
    • Oral retinoid
  • If female, subject is either not of , defined as for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of :

    • Condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD)
    • Contraceptives (oral or parenteral) for three months (90 days) prior to study drug administration
    • A vasectomized partner
    • Total abstinence from sexual intercourse
  • If female and of childbearing potential, the result of a serum pregnancy test performed at Screening is negative
  • Able and willing to self-administer sc injections or has available qualified person(s) to administer sc injections
  • Able and willing to give written and comply with the requirements of the study protocol

Exclusion criteria

Exclusion Criteria:

  • Subject has other active skin diseases or skin infections (bacterial, fungal, or viral) that may interfere with the evaluation of psoriasis or compromise the subject's safety
  • Subject has erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis as the primary morphology of their psoriasis
  • Subject has a history of an allergic reaction or significant sensitivity to constituents of adalimumab
  • agents not mentioned must be discontinued at least 30 days or 5 half-lives prior to the Baseline visit (whichever is longer)
  • Topical therapies:

    • Subject started receiving a new topical therapy within the last four weeks prior to the Baseline visit for areas other than the palms, soles of feet, axilla and groin.
    • Dose(s) and regimen(s) of topical therapy(ies) that the subject is receiving at the Baseline visit, for areas other than the palms, soles of feet, axilla and groin, was (were) increased during the four weeks that preceded the Baseline visit.
    • Subject is likely to require the initiation of a new topical therapy for the treatment of psoriasis such as , vitamin D analogs, or retinoids during the first 16 weeks that will follow the Baseline visit. (During the first 16 weeks that will follow the Baseline visit, initiation of topical therapies are allowed for the palms, soles of feet, axilla and groin area only).
  • Oral or injectable corticosteroids therapies:

    • Subject started receiving oral or injectable doses of corticosteroids within the last four weeks prior to the Baseline visit.
    • Dose(s) and regimen(s) of corticosteroids therapy(ies) that the subject is receiving at the Baseline visit, was (were) increased during the four weeks that preceded the Baseline visit.
    • Subject is likely to require the initiation of oral or injectable dose of corticosteroids therapies for the treatment of psoriasis during the first 16 weeks that will follow the Baseline visit.
  • Phototherapies

    • Subject started being treated with UVB phototherapy, within the last four weeks prior to the Baseline visit.
    • Regimen(s) of concomitant UVB phototherapy that the subject is receiving at the Baseline visit was (were) increased during the four weeks that preceded the Baseline visit.
    • Subject is likely to require the initiation of UVB therapy during the first 16 weeks that will follow the Baseline visit.
    • Subject was treated with psoralen UVA (PUVA) phototherapy within the last four weeks prior to the Baseline visit.
    • Subject is likely to require PUVA phototherapy during the course of the study.
    • Subject cannot avoid excessive sun exposure or the use of tanning booths for at least 2 weeks prior to Baseline and during the first 16 weeks that will follow the Baseline visit.
  • Systemic Therapies:

    • Subject has been initiated on a new systemic agent for the treatment of psoriasis within the last four weeks prior to the Baseline visit.
    • Dose(s) and regimen(s) of systemic therapy(ies) that the subject is receiving at the Baseline visit, was (were) increased during the four weeks that preceded the Baseline visit.
    • Subject is likely to require the initiation of systemic therapy, other than adalimumab, for the treatment of psoriasis during the first 16 weeks that will follow the Baseline visit.
    • Subject has been treated with systemic calcineurin inhibitors (cyclosporin, FK506 and others) within the last four weeks prior to the Baseline visit.
    • Subject is likely to receive systemic calcineurin inhibitors during the course of the study.
    • Subject has received Anakinra/Kineret within the last 2 weeks prior to the Baseline visit and is likely to receive Anakinra/Kineret during the course of the study.
  • Subject cannot discontinue the following systemic psoriasis therapies:

    • Alefacept must be discontinued at least 12 weeks prior to the Baseline visit.
    • Efalizumab must be discontinued at least 6 weeks prior to the Baseline visit.
    • Infliximab must be discontinued at least 8 weeks prior to the Baseline visit.
    • Etanercept must be discontinued at least 3 weeks prior to the Baseline visit.
  • Subject has a history of cancer or lymphoproliferative disease other than:

    • Successfully and completely treated Cervical dysplasia, with no recurrence within the last five years.
  • Has a history of uncontrolled diabetes, unstable ischemic heart disease, congestive heart failure, (NYHA) III, IV, recent stroke (within three months), chronic leg ulcer and any other condition (e.g., indwelling urinary catheter) which, in the opinion of the Investigator, would put the subject at risk by participation in the protocol or who would make the subject unsuitable for the study.
  • Positive serology for indicating acute or chronic infection.
  • Currently taking or likely to begin anti-retroviral therapy at any time during the course of the study.
  • Subject is known to have immune deficiency, history of (HIV) or is .
  • Persistent or recurrent or severe infections requiring hospitalization or treatment with intra-venous (IV) antibiotics within 30 days, or oral antibiotics within 14 days, prior to Baseline.
  • Female subjects who are pregnant or breastfeeding.
  • Has a history of drug or alcohol abuse in the last year.
  • Previous diagnosis or signs of central nervous system demyelinating diseases (e.g., optic neuritis, visual disturbance, gait disorder/ataxia, facial paresis, apraxia).
  • History of active tuberculosis (TB), history of histoplasmosis or listeriosis.
  • Has latent TB (positive purified protein derivative (PPD) skin test, two-step PPD when applicable, and chest X-ray indicative of TB) or has other risk factors for the activation of latent TB, e.g. previous exposure to TB, and has not initiated TB prophylaxis prior to the first adalimumab treatment. In either case, the Abbott Medical Advisor must be contacted before initiating the study treatment.
  • Subjects will be excluded if the CXR is found to have changes suggestive of old healed tuberculous lesion (e.g. calcified nodule, fibrotic scar, apical or basilar pleural thickening etc.).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    1

    Biological: Humira (adalimumab)

Interventions

  • Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.

    Also known as: ABT-D2E7, adalimumab, Humira

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Psoriasis Area and Severity Index (PASI) 75 Response at 16 Weeks

    PASI 75 is a 75% or greater improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree

    Time frame: 16 weeks

Secondary outcomes

  1. Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks

    Mean change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree

    Time frame: 16 and 24 weeks

  2. Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks

    Mean percent change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.

    Time frame: 16 and 24 weeks

  3. Number of Subjects With Improvement in Physician's Global Assessment for Psoriasis (PGA)

    Number of subjects with improvement on the Physician's Global Assessment for Psoriasis (PGA). The PGA is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject, where 0 = clear and 6 = very severe. Improvement is defined as a reduction in PGA score.

    Time frame: 16 and 24 weeks

  4. Number of Subjects Achieving a Clinical Response Defined as a Physician's Global Assessment for Psoriasis (PGA) of "Clear" or "Clear or Minimal"

    Number of subjects achieving a response of "Clear" or "Clear or Minimal" on the Physician's Global Assessment for Psoriasis. This is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Minimal, 2-Mild, 3-Moderate, 4-severe, 5-very severe.

    Time frame: 16 and 24 weeks

  5. Mean Change From Baseline in Physician Global Assessment of Arthritic Disease Activity at 16 and 24 Weeks

    Mean Change from Baseline in Physician Global Assessment of Arthritic Disease Activity as measured on a 100-mm visual analog scale where 0 mm = no arthritis activity and 100 mm = extremely active arthritis.

    Time frame: 16 and 24 weeks

  6. Number of Subjects With Psoriasis Area and Severity Index (PASI) 50/75/90/100 Response

    PASI 50/75/90/100 is a \>=50% / \>=75% / \>=90% / 100% improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.

    Time frame: 16 and 24 weeks

  7. Mean Change From Baseline in Tender Joint Count at 16 and 24 Weeks

    Mean change in the number of tender joints from Baseline. 78 joints were evaluated for tenderness, including all 76 joints evaluated for swelling plus the hip joints.

    Time frame: 16 and 24 weeks

  8. Mean Change From Baseline in Swollen Joint Count at 16 and 24 Weeks

    Mean change in the number of swollen joints from Baseline. 76 joints were evaluated for swelling, corresponding to all joints evaluated for tenderness except for the hip joints.

    Time frame: 16 and 24 weeks

  9. Mean Change From Baseline in Patient's Global Assessment of Joint Pain at 16 and 24 Weeks

    Mean change in the Patient's Global Assessment of Joint Pain from Baseline, as assessed on a 100-mm visual analog scale where 0 mm = no pain and 100 mm = pain as bad as it could be.

    Time frame: 16 and 24 weeks

  10. Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) at 16 and 24 Weeks

    Mean change in the Dermatology Life Quality Index (DLQI) from Baseline. The questionnaire contains 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired; the minimum clinically important difference is 2.3 to 5.7 point change.

    Time frame: 16 and 24 weeks

  11. Number of Subjects Achieving a Dermatology Life Quality Index (DLQI) = 0

    Number of subjects achieving a Dermatology Life Quality Index (DLQI) score of 0 (indicating total lack of impairment). The DLQI consists of 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired.

    Time frame: 16 and 24 weeks

  12. Mean Change From Baseline in Beck Depression Inventory (BDI-II) at 16 and 24 Weeks

    Change in the Beck Depression Inventory from Baseline. The BDI-II contains 21 questions and is scored from 0-63; higher scores indicate more severe depression symptoms.

    Time frame: 16 and 24 weeks

  13. Change From Baseline on the EuroQol (EQ-5D) Quality of Life Questionnaire

    Time frame: 16 and 24 weeks

  14. Change in Productivity Outcomes and Costs From Baseline as Measured by the Health and Labour Questionnaire (HLQ)

    Time frame: 16 and 24 weeks

  15. Change in Resource Utilization Outcomes and Costs From Baseline as Measured by the Health Care Resource (HCR) Questionnaire

    Time frame: 16 and 24 weeks

07

Results

Posted Nov 20, 2009

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab 40 mg Eow
Started203
Completed179
Not completed24

Outcome measures

PrimaryNumber of Subjects With Psoriasis Area and Severity Index (PASI) 75 Response at 16 Weeks

PASI 75 is a 75% or greater improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree

Time frame:
16 weeks
Reported as:
Number · participants
Number of Subjects With Psoriasis Area and Severity Index (PASI) 75 Response at 16 Weeks
participantsAdalimumab 40 mg Eow - 16 Weeks
Responder144
Non-responder47
SecondaryMean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks

Mean change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree

Time frame:
16 and 24 weeks
Reported as:
Mean · unit on a scale
Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks
unit on a scaleAdalimumab 40 mg Eow - 16 WeeksAdalimumab 40 mg Eow - 24 Weeks
Change from Baseline-15.9 ± 7.55-16.1 ± 7.46
SecondaryMean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks

Mean percent change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.

Time frame:
16 and 24 weeks
Reported as:
Mean · percent change
Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks
percent changeAdalimumab 40 mg Eow - 16 WeeksAdalimumab 40 mg Eow - 24 Weeks
Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks-81.5 ± 23.63-83.0 ± 23.47
SecondaryNumber of Subjects With Improvement in Physician's Global Assessment for Psoriasis (PGA)

Number of subjects with improvement on the Physician's Global Assessment for Psoriasis (PGA). The PGA is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject, where 0 = clear and 6 = very severe. Improvement is defined as a reduction in PGA score.

Time frame:
16 and 24 weeks
Reported as:
Number · participants
Number of Subjects With Improvement in Physician's Global Assessment for Psoriasis (PGA)
participantsAdalimumab 40 mg Eow - 16 WeeksAdalimumab 40 mg Eow - 24 Weeks
Number of Subjects With Improvement in Physician's Global Assessment for Psoriasis (PGA)174164
SecondaryNumber of Subjects Achieving a Clinical Response Defined as a Physician's Global Assessment for Psoriasis (PGA) of "Clear" or "Clear or Minimal"

Number of subjects achieving a response of "Clear" or "Clear or Minimal" on the Physician's Global Assessment for Psoriasis. This is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Minimal, 2-Mild, 3-Moderate, 4-severe, 5-very severe.

Time frame:
16 and 24 weeks
Reported as:
Number · participants
Number of Subjects Achieving a Clinical Response Defined as a Physician's Global Assessment for Psoriasis (PGA) of "Clear" or "Clear or Minimal"
participantsAdalimumab 40 mg Eow - 16 WeeksAdalimumab 40 mg Eow - 24 Weeks
Subjects achieving "Clear"5359
Subjects achieving "Clear or Minimal"111121
SecondaryMean Change From Baseline in Physician Global Assessment of Arthritic Disease Activity at 16 and 24 Weeks

Mean Change from Baseline in Physician Global Assessment of Arthritic Disease Activity as measured on a 100-mm visual analog scale where 0 mm = no arthritis activity and 100 mm = extremely active arthritis.

Time frame:
16 and 24 weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline in Physician Global Assessment of Arthritic Disease Activity at 16 and 24 Weeks
units on a scaleAdalimumab 40 mg Eow - 16 WeeksAdalimumab 40 mg Eow - 24 Weeks
Mean Change From Baseline in Physician Global Assessment of Arthritic Disease Activity at 16 and 24 Weeks-18.7 ± 23.48-20.9 ± 23.32
SecondaryNumber of Subjects With Psoriasis Area and Severity Index (PASI) 50/75/90/100 Response

PASI 50/75/90/100 is a \>=50% / \>=75% / \>=90% / 100% improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.

Time frame:
16 and 24 weeks
Reported as:
Number · participants
Number of Subjects With Psoriasis Area and Severity Index (PASI) 50/75/90/100 Response
participantsAdalimumab 40 mg Eow - 16 WeeksAdalimumab 40 mg Eow - 24 Weeks
Subjects achieving PASI 50169163
Subjects achieving PASI 75144140
Subjects achieving PASI 90100102
Subjects achieving PASI 1004958
SecondaryMean Change From Baseline in Tender Joint Count at 16 and 24 Weeks

Mean change in the number of tender joints from Baseline. 78 joints were evaluated for tenderness, including all 76 joints evaluated for swelling plus the hip joints.

Time frame:
16 and 24 weeks
Reported as:
Mean · number of joints
Mean Change From Baseline in Tender Joint Count at 16 and 24 Weeks
number of jointsAdalimumab 40 mg Eow - 16 WeeksAdalimumab 40 mg Eow - 24 Weeks
Mean Change From Baseline in Tender Joint Count at 16 and 24 Weeks-8.7 ± 13.57-8.7 ± 14.83
SecondaryMean Change From Baseline in Swollen Joint Count at 16 and 24 Weeks

Mean change in the number of swollen joints from Baseline. 76 joints were evaluated for swelling, corresponding to all joints evaluated for tenderness except for the hip joints.

Time frame:
16 and 24 weeks
Reported as:
Mean · number of joints
Mean Change From Baseline in Swollen Joint Count at 16 and 24 Weeks
number of jointsAdalimumab 40 mg Eow - 16 WeeksAdalimumab 40 mg Eow - 24 Weeks
Mean Change From Baseline in Swollen Joint Count at 16 and 24 Weeks-4.7 ± 5.35-4.9 ± 7.08
SecondaryMean Change From Baseline in Patient's Global Assessment of Joint Pain at 16 and 24 Weeks

Mean change in the Patient's Global Assessment of Joint Pain from Baseline, as assessed on a 100-mm visual analog scale where 0 mm = no pain and 100 mm = pain as bad as it could be.

Time frame:
16 and 24 weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline in Patient's Global Assessment of Joint Pain at 16 and 24 Weeks
units on a scaleAdalimumab 40 mg Eow - 16 WeeksAdalimumab 40 mg Eow - 24 Weeks
Mean Change From Baseline in Patient's Global Assessment of Joint Pain at 16 and 24 Weeks-20.9 ± 31.77-19.3 ± 32.02
SecondaryMean Change From Baseline in the Dermatology Life Quality Index (DLQI) at 16 and 24 Weeks

Mean change in the Dermatology Life Quality Index (DLQI) from Baseline. The questionnaire contains 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired; the minimum clinically important difference is 2.3 to 5.7 point change.

Time frame:
16 and 24 weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) at 16 and 24 Weeks
units on a scaleAdalimumab 40 mg Eow - 16 WeeksAdalimumab 40 mg Eow - 24 Weeks
Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) at 16 and 24 Weeks-9.8 ± 7.09-10.1 ± 7.26
SecondaryNumber of Subjects Achieving a Dermatology Life Quality Index (DLQI) = 0

Number of subjects achieving a Dermatology Life Quality Index (DLQI) score of 0 (indicating total lack of impairment). The DLQI consists of 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired.

Time frame:
16 and 24 weeks
Reported as:
Number · participants
Number of Subjects Achieving a Dermatology Life Quality Index (DLQI) = 0
participantsAdalimumab 40 mg Eow - 16 WeeksAdalimumab 40 mg Eow - 24 Weeks
Number of Subjects Achieving a Dermatology Life Quality Index (DLQI) = 06783
SecondaryMean Change From Baseline in Beck Depression Inventory (BDI-II) at 16 and 24 Weeks

Change in the Beck Depression Inventory from Baseline. The BDI-II contains 21 questions and is scored from 0-63; higher scores indicate more severe depression symptoms.

Time frame:
16 and 24 weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline in Beck Depression Inventory (BDI-II) at 16 and 24 Weeks
units on a scaleAdalimumab 40 mg Eow - 16 WeeksAdalimumab 40 mg Eow - 24 Weeks
Mean Change From Baseline in Beck Depression Inventory (BDI-II) at 16 and 24 Weeks-4.1 ± 6.56-4.3 ± 6.71
SecondaryChange From Baseline on the EuroQol (EQ-5D) Quality of Life Questionnaire
Time frame:
16 and 24 weeks
Reported as:
Mean · units on a scale

Results for this outcome have not been posted.

SecondaryChange in Productivity Outcomes and Costs From Baseline as Measured by the Health and Labour Questionnaire (HLQ)
Time frame:
16 and 24 weeks
Reported as:
Mean · units on a scale

Results for this outcome have not been posted.

SecondaryChange in Resource Utilization Outcomes and Costs From Baseline as Measured by the Health Care Resource (HCR) Questionnaire
Time frame:
16 and 24 weeks
Reported as:
Mean · units on a scale

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab 40 mg Eow———
Most frequent serious events
Most frequent serious events
EventAdalimumab 40 mg Eow
Myocardial infarctionCardiac disorders2/203
Tongue oedemaGastrointestinal disorders1/203
PericarditisCardiac disorders1/203
DeathGeneral disorders1/203
AppendicitisInfections and infestations1/203
PneumoniaInfections and infestations1/203
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/203
Renal vasculitisRenal and urinary disorders1/203
Stevens-Johnson syndromeSkin and subcutaneous tissue disorders1/203
Most frequent other events
Showing 10 of 27
Most frequent other events
EventAdalimumab 40 mg Eow
Upper respiratory tract infectionInfections and infestations22/203
NasopharyngitisInfections and infestations22/203
InfluenzaInfections and infestations10/203
HeadacheNervous system disorders10/203
ArthralgiaMusculoskeletal and connective tissue disorders8/203
Injection site reactionGeneral disorders7/203
PsoriasisSkin and subcutaneous tissue disorders7/203
HypertensionVascular disorders7/203
DiarrhoeaGastrointestinal disorders6/203
NauseaGastrointestinal disorders6/203

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Adalimumab 40 mg Eow
<=18 years0
Between 18 and 65 years192
>=65 years11
Age Continuous
Age Continuous(years)Adalimumab 40 mg Eow
Mean45.5 ± 12.34
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab 40 mg Eow
Female79
Male124
Region of Enrollment
Region of Enrollment(participants)Adalimumab 40 mg Eow
Canada203
08

Study locations

27 sites
  • Calgary, Alberta T2S 3B3, Canada
  • Calgary, Alberta T3A 2N1, Canada
  • Edmonton, Alberta T5K 1X3, Canada
  • Surrey, British Columbia V3R 6A7, Canada
  • Vancouver, British Columbia V5Z 4E8, Canada
  • Winnipeg, Manitoba R3C 0N2, Canada
  • Winnipeg, Manitoba R3C 1R4, Canada
  • Moncton, New Brunswick E1C 8X3, Canada
  • St. John's, Newfoundland and Labrador A1B 3E1, Canada
  • St. John's, Newfoundland and Labrador A1C 2H5, Canada
  • Halifax, Nova Scotia B3H 1Z4, Canada
  • Barrie, Ontario L4M 6L2, Canada
  • Fenwick, Ontario L0S 1C0, Canada
  • Hamilton, Ontario L8N 1V6, Canada
  • London, Ontario N5X 2P1, Canada
  • London, Ontario N6A 3H7, Canada
  • Markham, Ontario L3P 1A8, Canada
  • Nepean, Ontario K2G 6E2, Canada
  • North Bay, Ontario P1B 3Z7, Canada
  • Oakville, Ontario L6J 7W5, Canada
  • Oakville, Ontario L6K 1E1, Canada
  • Toronto, Ontario M4V 1R1, Canada
  • Waterloo, Ontario N2J 1C4, Canada
  • Montreal, Quebec H3Z 2S6, Canada
  • Sherbrooke, Quebec J1H 1Z1, Canada
  • Ste-Foy, Quebec G1V 4X7, Canada
  • Quebec, G1J 1X7, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007 and a primary completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2007
First posted
Aug 8, 2007
Start
Sep 2007
Primary completionActual
Sep 2008
Results first posted
Nov 20, 2009
Last update
Apr 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00513370
Lead sponsor
Abbott
First posted
Aug 8, 2007
Start date
Sep 2007
Primary completion
Sep 2008
Results posted
Nov 20, 2009
Last update
Apr 11, 2011

Study contacts

Kim Papp, MD PhD FRCPC
principal investigator · K. Papp Clinical Research Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion